WHO ICTRP trial
A study comparing Emicizumab and Extended Half-Life Factor VIII for reducing…
CTRI/2025/11/096854 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/11/096854 |
|---|---|
| Public title | A study comparing Emicizumab and Extended Half-Life Factor VIII for reducing bleeding episodes in Hemophilia A patients without inhibitors. |
| Scientific title | A pilot Randomised Control Trial comparing the efficacy and safety of Standard Dose and Low dose Emicizumab prophylaxis with Extended Half Life Factor VIII concentrate in children with severe Hemophilia A without Inhibitors - NIL |
| Primary sponsor | NIL |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: D66- Hereditary factor VIII deficiency |
| Interventions | Intervention1: Standard Dose Emicizumab prophylaxis: Patients will receive prophylaxis with emicizumab, administered subcutaneously at standard dose regimen (loading dose 3 mg/kg weekly for 4 weeks followed by maintenance dose 3 mg/kg every… |
| Registration date | Mar 11, 2025 |
| Target size | 30 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: